^
Association details:
| Biomarker: | ALK rearrangement |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P38.05 - Clinical, Genetic, Radiological, and Pathological Characteristics of Cribriform Adenocarcinoma of the Lung
Published date:
01/12/2021
Excerpt:
Twenty-five patients (2.4%) had Cribri-ADC….Among the 10 patients who had tumor recurrences, 8 had EGFR mutations or ALK rearrangement, 6 of whom achieved relatively long survival (median, 64.6 months; range, 37.4–113 months) following treatment with tyrosine kinase inhibitors (TKIs).
